Zobrazeno 1 - 10
of 80
pro vyhledávání: '"E. Temmer"'
Autor:
McIntosh, Scott W.1,2 smcintosh@lynker.com, Leamon, Robert J.1,3,4, Choudhary, Debi Prasad5, Fernandes, João Manuel6
Publikováno v:
Frontiers in Astronomy & Space Sciences. 2024, p1-13. 13p.
Autor:
Kaportseva, Ksenia1,2 kb.kaportceva@physics.msu.ru, Shugay, Yulia1, Vakhrusheva, Anna1,2, Kalegaev, Vladimir1,2, Shiryaev, Anton1,3, Eremeev, Valeriy1
Publikováno v:
Universe (2218-1997). Aug2024, Vol. 10 Issue 8, p321. 22p.
Autor:
M. von Mehren, Jonathan D. Cheng, E. Temmer, Z. Yuan, F. G. Renshaw, P. Zannikos, E. Bayever, Roger B. Cohen, Russell J. Schilder, T. M. Cardoso
To determine the maximum tolerated dose (MTD), safety, potential pharmacokinetic (PK) interactions, and effect on liver histology of trabectedin in combination with pegylated liposomal doxorubicin (PLD) for advanced malignancies.Entry criteria for th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d812f4037f378e4b2513d45abb0932d4
https://europepmc.org/articles/PMC2598415/
https://europepmc.org/articles/PMC2598415/
Autor:
Cindy L. O'Bryant, F. Fox, E. Temmer, S. G. Eckhardt, L.Q. Chow, Lia Gore, H. Youssoufian, D.R. Camidge, Sami Diab, R.B. Cohen
Publikováno v:
European Journal of Cancer Supplements. 4:195
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e92fae7471eb92dce162d9583abca904
https://doi.org/10.1016/s1359-6349(06)70652-8
https://doi.org/10.1016/s1359-6349(06)70652-8
Autor:
L. Maloney, S. Brown, R.B. Cohen, C. Morris, A. Adjei, J. Molina, E. Temmer, S. Hariharan, S. G. Eckhardt, Wilbur A. Franklin
Publikováno v:
European Journal of Cancer Supplements. 4:12
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91ffcbd1fc0ba59e98cd4459521abe46
https://doi.org/10.1016/s1359-6349(06)70031-3
https://doi.org/10.1016/s1359-6349(06)70031-3
Publikováno v:
Journal of Clinical Oncology. 24:2068-2068
2068 Background: T is a novel cytotoxic agent that binds to the DNA minor groove and is active in several tumor types. The objective of this study is to determine the maximum tolerated dose (MTD) of the combination. Other objectives include safety an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66e6aaea7f92ba2cb9553fad5179a86d
https://doi.org/10.1200/jco.2006.24.18_suppl.2068
https://doi.org/10.1200/jco.2006.24.18_suppl.2068
Autor:
Roger B. Cohen, Cindy L. O'Bryant, E. Temmer, Floyd Fox, T. Katz, A. Ervin-Haynes, Sami Diab, Laura Q.M. Chow, Lia Gore, D.R. Camidge, S. G. Eckhardt
Publikováno v:
Journal of Clinical Oncology. 24:3032-3032
3032 Background: Anti-VEGFR2 antibodies are effective in a variety of preclinical leukemia and solid tumor models. IMC-1121B is a fully human anti-VEGFR2 IgG1 Mab. Methods: Cohorts of 3–6 pts (ECOG PS ≤ 2) with advanced cancer and no significant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ee1232cbd055e5e452ce9f5c2173cb6c
https://doi.org/10.1200/jco.2006.24.18_suppl.3032
https://doi.org/10.1200/jco.2006.24.18_suppl.3032
Autor:
Chi, Yutian, Shen, Chenglong, Zhang, Zhiyong, Xu, Mengjiao, Mao, Dongwei, Liu, Junyan, Wang, Can, Yu, Bingkun, Luo, Jingyu, Zhong, Zhihui, Wang, Yuming
Publikováno v:
Astrophysical Journal Letters; 11/10/2024, Vol. 975 Issue 2, p1-9, 9p
Publikováno v:
Astrophysical Journal; 10/20/2024, Vol. 974 Issue 2, p1-15, 15p
Publikováno v:
Geofizika. 2023, Vol. 40 Issue 2, p210-225. 16p.